Entourage Health Report First Quarter 2024 Financial Results - Total revenue of $16.4 million represents a 9% increase year-over-year and a 23% sequential increase from Q4 2023.
- Gross profit before fair value changes improved by 92% year-over-year, leading to a record gross margin of 45%. This achievement reflects the successful execution of last year’s transformation plans.
- EBITDA improved by $4.4 million, marking the Company's first positive quarter and resulting in a 114% year-over-year improvement.**
- Adult-use revenue reported a 10% increase year-over-year, highlighting expanding market share.
- Management will host a conference call on May 28, 2024, at 10 a.m. Eastern Time.
TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products, today announced its financial results for the three months ended March 31, 2024. The Company reported total revenue of $16.4 million (net revenue of $12.7 million, before excise duties and discounts), up 9% year-over-year. The Company will host a conference call to discuss its financial and business highlights on Tuesday, May 28, 2024, at 10:00 a.m. Eastern Time.
Entourage Health Reports First Quarter 2024 Financial (globenewswire.com)